JP6871638B2 - 肝癌の治療または予防用組成物 - Google Patents

肝癌の治療または予防用組成物 Download PDF

Info

Publication number
JP6871638B2
JP6871638B2 JP2018561462A JP2018561462A JP6871638B2 JP 6871638 B2 JP6871638 B2 JP 6871638B2 JP 2018561462 A JP2018561462 A JP 2018561462A JP 2018561462 A JP2018561462 A JP 2018561462A JP 6871638 B2 JP6871638 B2 JP 6871638B2
Authority
JP
Japan
Prior art keywords
hepatocellular carcinoma
cells
pi3k
hcc
ros
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018561462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510075A (ja
JP2019510075A5 (enExample
Inventor
グフン チョン
グフン チョン
ユンギョン コ
ユンギョン コ
ユンジュン キム
ユンジュン キム
Original Assignee
マスターメディテック インコーポレーテッド
マスターメディテック インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マスターメディテック インコーポレーテッド, マスターメディテック インコーポレーテッド filed Critical マスターメディテック インコーポレーテッド
Publication of JP2019510075A publication Critical patent/JP2019510075A/ja
Publication of JP2019510075A5 publication Critical patent/JP2019510075A5/ja
Application granted granted Critical
Publication of JP6871638B2 publication Critical patent/JP6871638B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018561462A 2016-02-15 2017-02-14 肝癌の治療または予防用組成物 Active JP6871638B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020160017187A KR101662975B1 (ko) 2016-02-15 2016-02-15 간암 치료 또는 예방용 조성물
KR10-2016-0017187 2016-02-15
PCT/KR2017/001575 WO2017142283A1 (ko) 2016-02-15 2017-02-14 간암 치료 또는 예방용 조성물

Publications (3)

Publication Number Publication Date
JP2019510075A JP2019510075A (ja) 2019-04-11
JP2019510075A5 JP2019510075A5 (enExample) 2020-02-13
JP6871638B2 true JP6871638B2 (ja) 2021-05-12

Family

ID=57164552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018561462A Active JP6871638B2 (ja) 2016-02-15 2017-02-14 肝癌の治療または予防用組成物

Country Status (5)

Country Link
US (1) US10463669B2 (enExample)
JP (1) JP6871638B2 (enExample)
KR (1) KR101662975B1 (enExample)
CN (1) CN109069513B (enExample)
WO (1) WO2017142283A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101662975B1 (ko) * 2016-02-15 2016-10-06 서울대학교산학협력단 간암 치료 또는 예방용 조성물
WO2019121872A1 (en) * 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
CN110665007A (zh) * 2019-09-19 2020-01-10 邦世（苏州）生物医药科技有限公司 一种治疗癌症用组合药物及其用途
KR102699871B1 (ko) 2021-04-29 2024-08-29 주식회사 서지넥스 약물전달물질로서의 간세포암 특이적 표적 엑소좀 조성물 및 이의 용도
KR20230112770A (ko) 2022-01-20 2023-07-28 가톨릭대학교 산학협력단 항섬유화 억제용 조성물
CN114796482A (zh) * 2022-05-31 2022-07-29 江苏省人民医院（南京医科大学第一附属医院） gsk3β抑制剂在制备提高抗肝细胞肝癌疗效的药物中的应用
KR20250044972A (ko) 2023-09-25 2025-04-01 주식회사 마스터메디텍 이델라리십 함유 경구투여용 고형제제 및 그 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2421536B1 (en) * 2009-04-20 2015-08-26 Gilead Calistoga LLC Methods of treatment for solid tumors
US8691829B2 (en) * 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
WO2013082540A1 (en) * 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
WO2014046617A1 (en) * 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions and methods for treating cancer
KR101418161B1 (ko) * 2012-09-26 2014-07-09 부경대학교 산학협력단 네퍼린을 유효성분으로 포함하는 간암 예방 또는 치료용 약제학적 조성물
CA2915250A1 (en) * 2013-06-13 2015-01-08 Biomatrica, Inc. Cell stabilization
CN104817559B (zh) * 2014-01-30 2021-05-25 苏州泽璟生物制药股份有限公司 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
WO2016097314A1 (en) * 2014-12-19 2016-06-23 Sandoz Ag Amorphous and crystalline forms of idelalisib and process for forming the same
KR101662975B1 (ko) * 2016-02-15 2016-10-06 서울대학교산학협력단 간암 치료 또는 예방용 조성물

Also Published As

Publication number Publication date
CN109069513B (zh) 2021-12-28
WO2017142283A1 (ko) 2017-08-24
CN109069513A (zh) 2018-12-21
US20190160073A1 (en) 2019-05-30
JP2019510075A (ja) 2019-04-11
KR101662975B1 (ko) 2016-10-06
US10463669B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
JP6871638B2 (ja) 肝癌の治療または予防用組成物
Zhang et al. PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma
Guo et al. Macrophage migration inhibitory factor promotes vasculogenic mimicry formation induced by hypoxia via CXCR4/AKT/EMT pathway in human glioblastoma cells
Du et al. Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice
US9187787B2 (en) Method of diagnosing and treating cancer
Yuan et al. TIPE3 is a regulator of cell apoptosis in glioblastoma
Kunanopparat et al. Increased ATG5-ATG12 in hepatitis B virus-associated hepatocellular carcinoma and their role in apoptosis
Liu et al. Neutrophil extracellular traps promote gastric cancer cell metastasis via the NAT10-mediated N4-acetylcytidine modification of SMYD2
US8513028B2 (en) Use of MLN51 gene and protein
Tu et al. CD164 regulates proliferation and apoptosis by targeting PTEN in human glioma
Guo et al. Ubiquitin-conjugating enzyme E2T knockdown suppresses hepatocellular tumorigenesis via inducing cell cycle arrest and apoptosis
Lin et al. TRPM7 facilitates fibroblast-like synoviocyte proliferation, metastasis and inflammation through increasing IL-6 stability via the PKCα-HuR axis in rheumatoid arthritis
JP2016525874A (ja) ガンを治療するための療法のための標的として使用するためのｆａｌｚ
Xian et al. SNORD99 promotes endometrial cancer development by inhibiting GSDMD‐mediated pyroptosis through 2'‐O‐methylation modification
Shu et al. Functional characterization of the long noncoding RNA MIR22HG as a tumour suppressor in cervical cancer by targeting IGF2BP2.
WO2020113877A1 (zh) E2f6抑制剂的功能与用途
Struve et al. Increased replication stress and R-loop accumulation in EGFRvIII-expressing glioblastoma present new therapeutic opportunities
WO2011129427A9 (ja) 癌の診断剤および治療剤
CN105457041A (zh) miR-26a在非小细胞肺癌中的应用
WO2019036174A1 (en) METHODS AND COMPOSITIONS RELATED TO ANTI-CALCIFICATION
US10125358B2 (en) Methods and compounds for increasing threonyl-tRNA synthetase activity
Spalinger et al. Tofacitinib Mitigates the Increased SARS-CoV-2 Infection Susceptibility Caused by an IBD Risk Variant in the PTPN2 Gene
Qu et al. E2F2 serves as an essential prognostic biomarker and therapeutic target for human renal cell carcinoma by presenting “E2F2/miR-16–5p/SPTLC1” schema
CN118286467B (zh) 整合应激反应抑制剂isrib在治疗肝癌中的应用
Degorre et al. Mechanistic insights of radiation-induced endothelial senescence impelling glioblastoma genomic instability at relapse

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190128

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191225

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200720

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210330

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210409

R150 Certificate of patent or registration of utility model

Ref document number: 6871638

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250